Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.

Journal Article (Journal Article)

Background: The RV144 ALVAC-HIV prime, AIDSVAX B/E boost afforded 60% efficacy against human immunodeficiency virus (HIV) acquisition at 1 year, waning to 31.2% after 3.5 years. We hypothesized that additional vaccinations might augment immune correlates of protection. Methods: In a randomized placebo-controlled double-blind study of 162 HIV-negative RV144 vaccine recipients, we evaluated 2 additional boosts, given 6-8 years since RV144 vaccination, for safety and immunogenicity, at weeks 0 and 24. Study groups 1-3 received ALVAC-HIV+AIDSVAX B/E, AIDSVAX B/E, and ALVAC-HIV, respectively, or placebo. Results: Vaccines were well tolerated. For groups 1 and 2, plasma immunoglobulin (Ig) G, IgA, and neutralizing antibody responses at week 2 were all significantly higher than 2 weeks after the last RV144 vaccination. IgG titers against glycoprotein (gp) 70V1V2 92TH023 increased 14-fold compared with 2 weeks after the last RV144 vaccination (14069 vs 999; P < .001). Groups 1 and 2 did not differ significantly from each other, whereas group 3 was similar to placebo recipients. Responses in groups 1 and 2 declined by week 24 but were boosted by the second vaccination, albeit at lower magnitude than for week 2. Conclusions: In RV144 vaccinees, AIDSVAX B/E with or without ALVAC-HIV 6-8 years after initial vaccination generated higher humoral responses than after RV144, but these responses were short-lived, and their magnitude did not increase with subsequent boost. Clinical Trials Registration: NCT01435135.

Full Text

Duke Authors

Cited Authors

  • Rerks-Ngarm, S; Pitisuttithum, P; Excler, J-L; Nitayaphan, S; Kaewkungwal, J; Premsri, N; Kunasol, P; Karasavvas, N; Schuetz, A; Ngauy, V; Sinangil, F; Dawson, P; deCamp, AC; Phogat, S; Garunathan, S; Tartaglia, J; DiazGranados, C; Ratto-Kim, S; Pegu, P; Eller, M; Karnasuta, C; Montefiori, DC; Sawant, S; Vandergrift, N; Wills, S; Tomaras, GD; Robb, ML; Michael, NL; Kim, JH; Vasan, S; O'Connell, RJ; RV305 Study Team,

Published Date

  • April 15, 2017

Published In

Volume / Issue

  • 215 / 8

Start / End Page

  • 1255 - 1263

PubMed ID

  • 28329190

Pubmed Central ID

  • PMC5853427

Electronic International Standard Serial Number (EISSN)

  • 1537-6613

Digital Object Identifier (DOI)

  • 10.1093/infdis/jix099


  • eng

Conference Location

  • United States